Mood Disorders News

Psychotic-like experiences, circadian disturbances, poorer social function and manic-like experiences were linked to illness progression in a longitudinal cohort study of youth who presented to early intervention services for psychiatric disorders.

Thyroid-stimulating hormone concentrations were abnormal in about 6% of psychiatrically hospitalized youth with significant mood and anxiety disorders, but thyroid disease was present in less than 1% of the total sample, according to study findings.

Study findings published in PLOS Biology indicated that air pollution was significantly linked to increased risk for psychiatric disorders in the United States and Denmark.

Continuing sertraline plus olanzapine compared with sertraline plus placebo reduced the risk for relapse over 36 weeks among adults with psychotic depression in remission, study findings published in JAMA showed.

Adding fluoxetine to cognitive behavioral therapy failed to further decrease depressive symptoms in youth with moderate-to-severe major depressive disorder, according to findings published in Lancet Psychiatry.

Among adolescents and adults with congenital heart disease, mental illness is a significantly more prevalent comorbidity in those who experienced at least two cardiac procedures during a 3-year period or had greater lesion complexity than in others.

Adults with cerebral palsy, particularly those with neurodevelopmental disorders, have increased risk for mental health disorders compared with adults without cerebral palsy, according to a study published in the Annals of Internal Medicine.

Massachusetts General Hospital has been named the number one hospital for psychiatric care in America for 2019 to 2020, according to the U.S. News & World Report.

Although benzodiazepine use during pregnancy did not seem to be linked to congenital or cardiac malformations, its use in combination with antidepressants may increase the risk for congenital malformations, study data published in Journal of Clinical Psychiatry showed.

The FDA has issued a warning letter to Curaleaf Inc. for illegally selling unapproved products containing cannabidiol, or CBD, online, claiming to treat Alzheimer’s disease, cancer, opioid withdrawal, pain and other conditions, according to a press release.